Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Time-Limited Acalabrutinib/Obinutuzumab Produces Durable Responses in Treatment-Naive CLL

July 25th 2024

Time-limited acalabrutinib plus obinutuzumab produced responses in treatment-naive chronic lymphocytic leukemia.

MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer

July 25th 2024

Lajos Pusztai, MD, DPhil, discusses molecular residual disease monitoring in early-stage breast cancer.

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

July 24th 2024

Drs Park and Sonpavde discuss findings from the phase 1 DAD trial, as well as a schema for the frontline management of metastatic urothelial carcinoma.

Fixed-Duration Venetoclax-Based Combos Maintain Benefit in Frontline CLL

July 17th 2024

Moritz Fürstenau, MD, discusses 4-year follow-up findings from the phase 3 GAIA/CLL13 trial in patients with CLL.

Pelabresib/Ruxolitinib Data Underscore Need for Novel End Points in Myelofibrosis Trials

July 15th 2024

Aaron Gerds, MD discusses updated efficacy findings from the prospective randomized phase 3 MANIFEST-2 trial.

Observational MOST Trial Reveals Progression Trends in Low-Risk Myelofibrosis

July 11th 2024

Aaron Gerds, MD, discusses progression data for patients with low- or intermediate-1–risk myelofibrosis in the MOST trial.

Neoadjuvant Cemiplimab Underscores Push to Bolster Treatment of CSCC

July 10th 2024

Neil D. Gross, MD, FACS, discusses the neoadjuvant use of cemiplimab for the treatment of cutaneous squamous cell carcinoma.

Myeloma Data Presented at ASCO Highlight Continued Evolution of Treatment Paradigm

July 9th 2024

Noa Biran, MD, discusses key data from clinical trials in multiple myeloma presented at the 2024 ASCO Annual Meeting.

Neoadjuvant Sacituzumab Govitecan Data Draw Curiosity in Cisplatin-Ineligible MIBC

July 9th 2024

Antonio Cigliola, MD, discusses the evaluation of neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer.

Tazemetostat Plus Pembrolizumab Is Tolerable in Advanced Urothelial Carcinoma

July 8th 2024

Tazemetostat plus pembrolizumab was tolerable in platinum-exposed or -ineligible advanced urothelial carcinoma.

Investigating Risk-Based Treatment Strategies for Pediatric Non-Rhabdomyosarcoma Soft-Tissue Sarcoma

July 7th 2024

Robert Lawrence Randall, MD, FACS, discusses the significance of risk-based therapy in patients with non-rhabdomyosarcoma soft tissue sarcoma.

First-Line Orelabrutinib Plus FCG Generates Rapid Molecule Remissions in CLL

July 3rd 2024

Orelabrutinib plus FCG led to undetectable MRD in all patients with untreated chronic lymphocytic leukemia who completed 12 cycles of therapy

Belantamab Mafodotin–Based Combo Boosts PFS in Difficult-to-Treat R/R Myeloma Subgroups

July 1st 2024

María-Victoria Mateos, MD, PhD, discusses subgroup results for belantamab mafodotin plus bortezomib/dexamethasone in relapsed/refractory myeloma

Do Tumor-Naive MRD Assays Have a Role in Resected CRC? Cremolini Weighs in

June 28th 2024

Chiara Cremolini, MD, discusses the role of ctDNA in assessing minimal residual disease in patients with CRC.

Intrathecal Dendritic Cells Under Evaluation for Leptomeningeal Disease in TNBC and HER2+ Breast Cancer

June 26th 2024

Peter Forsyth, MD, on the investigation of intrathecal dendritic cells for leptomeningeal disease in triple-negative and HER2-positive breast cancer.

Sacituzumab Govitecan/Enfortumab Vedotin ± Pembrolizumab Under Investigation in Metastatic Urothelial Carcinoma

June 26th 2024

Bradley McGregor, MD, on the ongoing evaluation of sacituzumab govitecan plus enfortumab vedotin with or without pembrolizumab in urothelial carcinoma.

ARASENS Trial Demonstrates Significant Survival Benefits With Triplet Therapy in mHSPC

June 25th 2024

Darolutamide plus ADT and docetaxel showed improved outcomes in patients with metastatic hormone-sensitive prostate cancer.

Fixed-Duration Glofitamab Yields Responses in R/R Mantle Cell Lymphoma

June 18th 2024

Tycel Phillips, MD, discusses updated findings from a phase 1/2 trial evaluating glofitamab in relapsed/refractory mantle cell lymphoma.

DESTINY-Breast06 Data Reveal Another Potential Avenue for T-DXd in HR+, HER2-Low Metastatic Breast Cancer

June 13th 2024

VK Gadi, MD, PhD, discusses findings from the DESTINY-Breast06 trial and the implications for hormone receptor–positive, HER2-low metastatic breast cancer.

Long-Term Data for Up-Front Combinations Reaffirm Treatment Options in CLL

June 11th 2024

Kathleen A. Dorritie, MD, discusses long-term data from trials in chronic lymphocytic leukemia presented at the 2023 ASH Annual Meeting.